These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35462358)

  • 21. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series.
    Ruiz-Villaverde R; Dominguez-Cruz J; Armario-Hita JC; Martinez-Pilar L; Alcantara-Luna S; Pereyra-Rodriguez JJ
    Dermatol Ther; 2019 Jul; 32(4):e12931. PubMed ID: 30980485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of dupilumab for atopic dermatitis in young transplant patients-A case series of 3 patients.
    Steele MV; Gupta R; Maguiness S; Boull C
    Pediatr Dermatol; 2023; 40(5):897-899. PubMed ID: 36815666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

  • 26. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab.
    Cho MK; Shin JU; Kim DH; Lee HJ
    Clin Exp Dermatol; 2022 Dec; 47(12):2303-2305. PubMed ID: 36006169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occupational Chronic Hand Dermatitis in Hospital Environment Successfully Treated with Dupilumab: A Case Report.
    Gan H; Gao YD
    Iran J Allergy Asthma Immunol; 2022 Aug; 21(4):484-487. PubMed ID: 36243937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
    J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occupational skin allergies: testing and treatment (the case of occupational allergic contact dermatitis).
    Holness DL
    Curr Allergy Asthma Rep; 2014 Feb; 14(2):410. PubMed ID: 24408535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Liberman P; Shifera AS; Berkenstock M
    Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina].
    Máspero J; Angles MV; Ardusso L; Brancciforte M; Castro C; Cruz Iturrieta C; Chouela E; De Gennaro MS; Fernández Bussy R; Galimberti ML; Galimberti RL; Gattolin G; Luna PC; Magariños G; Marini MG; Maskin M; Plafnik R; Raimondo N; Russo JP; Sevinsky L; Stringa MF
    Rev Fac Cien Med Univ Nac Cordoba; 2020 Jun; 77(2):94-99. PubMed ID: 32558511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
    Lor M; Villa N; Holland V
    Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atopic dermatitis-like graft-versus-host disease treated with dupilumab.
    Larijani M; Zarowin D; Wohlschlaeger A; Perman MJ; Treat JR
    Pediatr Dermatol; 2023 Mar; 40(2):320-322. PubMed ID: 36268606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
    Silverberg JI; Simpson EL; Boguniewicz M; De Bruin-Weller MS; Foley P; Kataoka Y; Bégo-Le-Bagousse G; Chen Z; Shumel B; Chao J; Rossi AB
    Acta Derm Venereol; 2021 Nov; 101(11):adv00585. PubMed ID: 34618162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis.
    Chipalkatti N; Lee N; Zancanaro P; Dumont N; Kachuk C; Rosmarin D
    J Am Acad Dermatol; 2019 Apr; 80(4):1166-1167. PubMed ID: 30630024
    [No Abstract]   [Full Text] [Related]  

  • 38. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 39. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review.
    Avallone G; Trunfio M; Giura MT; Siliquini N; Viola R; Orofino G; Mastorino L; Ortoncelli M; Quaglino P; Ribero S
    Dermatol Online J; 2021 Aug; 27(8):. PubMed ID: 34755964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.
    Cioppa V; Lazzeri L; Carraro A; De Piano E; Falcinelli F; Galluzzo M; Pallotta S; De Pità O; Russo F
    Dermatitis; 2024; 35(S1):S107-S108. PubMed ID: 37594754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.